Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People who received a shortened course of antiviral therapy were less likely to be cured.
Timely testing and treatment could improve outcomes for young people who inject drugs.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
Barriers still stand in the way of making treatment available to all who need it.
The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.
Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
Pharmacist-driven hep C treatment sees good cure rates
Researchers conducted an analysis of hep C treatment outcomes in those also living with HIV in Western nations.
Large European study finds that more than 1 in 10 people with HIV acquire HCV again.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.
Those with greater fibrosis before treating hep C see the greatest benefit.
Research found that healthcare providers could do better at preventing drug interactions.
People who have a low CD4 count, have cirrhosis and take certain hep C drug regimens are less likely to be cured.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.